Coenzyme Q10 in Pediatric Community-Acquired Pneumonia

Tanta University

Status: Not yet enrolling

Conditions: Community Acquired Pneumonia

Treatments: Drug: oral coenzymeQ10

Study type: Interventional

Funder types: Other

Identifiers

NCT07317440

36264PR1169/3/25

Details and patient eligibility

About

The aim of this work is to assess the benefit of coenzyme Q10 supplementation, in addition to standard antibiotic and other supportive therapy, in the management of hospitalized children with community acquired pneumonia

Enrollment: 120 estimated patients

Sex: All

Ages: 2 months to 18 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• All children aged 2 months -18 years with community acquired pneumonia diagnosed by signs and symptoms of CAP including; chest pain, dyspnea, tachypnea, or abnormal auscultatory findings plus focal findings on chest x ray indicating community acquired pneumonia

Exclusion criteria

• Children with immunodeficiency, chronic lung disease, malignancy, congenital lung anomalies, underlying disorder impacting respiration i.e. genetic, metabolic, neuromuscular disorders, children with CHD affecting the pulmonary blood flow.

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: None (Open label)

---

120 participants in 2 patient groups

60 children with community acquired pneumonia will receive oral coenzymeQ10

Experimental group

Treatment:

Drug: oral coenzymeQ10

60 children with community acquired pneumonia with the standard pneumonia treatment.

No Intervention group